Meeting
2014 ASCO Annual Meeting
Effect of afatinib alone and in combination with dasatinib in triple-negative breast cancer cell lines.
Authors
Mohamed F.K. Ibrahim
Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin, Ireland
Mohamed F.K. Ibrahim , Alexandra Canonici , Denis Collins , John Crown , Norma O'Donovan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1128)
DOI
10.1200/jco.2014.32.15_suppl.1128
Abstract #
1128
Poster Bd #
221
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Frequency of HER2 mutations and amplification in GI malignancies and ability of pertuzumab to overcome neuregulin1 mediated drug resistance to a HER2 tyrosine kinase inhibitor in colon cancer.
First Author: Ron Bose
Poster
2023 ASCO Annual Meeting
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
First Author: John Heymach
Poster
2021 ASCO Annual Meeting
Mutational analysis of rare insertions and deletions in exon 18 and 19 of HER2 in Chinese patients with different cancer types.
First Author: Jianwen Qin
Poster
2019 ASCO Annual Meeting
Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis.
First Author: Hiroe Kayatani